ovarian cancer

Oncology-focused biopharmaceutical company Tesaro has started patient enrolment in a Phase III trial of an inhibitor of poly ADP-ribose polymerase (PARP), niraparib, for ovarian cancer.

Referred to as Niraparib Ovarian (NOVA), the study is designed to assess a single daily 300mg dose of niraparib in 360 patients with high grade serous, platinum sensitive, relapsed ovarian cancer against placebo.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Tesaro president Dr Mary Lynne Hedley said: "This milestone represents a significant advance in the progression of TESARO’s pipeline and brings us closer to our goal of delivering new oncology therapies to patients."

The double blind, placebo-controlled, international trial of niraparib will enrol 360 patients into one of the two independent cohorts based on germline BRCA mutation status.

"This milestone represents a significant advance in the progression of TESARO’s pipeline and brings us closer to our goal of delivering new oncology therapies to patients."

Patients will be randomised to receive niraparib or placebo in the ratio 2:1 within each cohort and the treatment will continue until progression.

See Also:

The study’s primary endpoint is progression free survival and secondary endpoints include patient reported outcomes, chemotherapy free interval length, and overall survival.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

At the recommended dose, Phase I trial of niraparib demonstrated that a RECIST response rate of 75% was observed with platinum sensitive high grade serous ovarian cancer, 46% in the population across all dose levels and 50% in patients with platinum sensitive ovarian cancer and germline BRCA mutations.

The study, in which Niraparib was well tolerated, noted a median duration of response of 431 days for platinum sensitive germline BRCA patients and 444 days for platinum sensitive patients who were not germline BRCA mutation carriers.

Image: An ovarian cancer as seen on CT. Photo: courtesy of James Heilman.